Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)
Status:
Completed
Trial end date:
2007-02-16
Target enrollment:
Participant gender:
Summary
This multicenter, randomized, double-blind, placebo-controlled study will assess, after 6
weeks of dosing, whether co-administration of ezetimibe 10 mg with simvastatin 20 mg will be
more effective than treatment with doubling the dose of simvastatin to 40 mg alone in
reducing low-density lipoprotein-cholesterol (LDL-C) concentrations and in achieving the
National Cholesterol Expert Panel (NCEP) III LDL-C target goal of <2.6 mmol/L (<100 mg/dL)
for subjects with diabetes mellitus and coronary heart disease.